.png "Genomic Health (NASDAQ: GHDX)")
Today, the CSO of Genomic Health (GHDX), Steven Shak, bought shares of GHDX for $911.6K.
This recent transaction increases Steven Shak’s holding in the company by 9.91% to a total of $25.66 million. In addition to Steven Shak, 5 other GHDX executives reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Based on Genomic Health’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $105 million and quarterly net profit of $8.91 million. In comparison, last year the company earned revenue of $87.46 million and had a net profit of $1.88 million. GHDX’s market cap is $2.79B and the company has a P/E ratio of 113.28. Currently, Genomic Health has an average volume of 334.9K.
Based on 6 analyst ratings, the analyst consensus is Hold with an average price target of $80.60, reflecting a 6.7% upside.
In the last 30 days, insiders have sold $3.25M worth of GHDX shares and purchased $4.09M worth of GHDX shares. The insider sentiment on Genomic Health has been positive according to 125 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Genomic Health, Inc. provides genomic-based diagnostic tests, which analyze the underlying biology of cancers, allowing physicians and patients to make individualized treatment decisions. It uses a platform which translates a massive amount of clinical and genomic data into clinically actionable results for treatment planning.
